MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

Home » BD recalls hundreds of thousands of Alaris pumps due to multiple issues

BD recalls hundreds of thousands of Alaris pumps due to multiple issues

By

Becton DickinsonThe FDA today warned on a Class I recall of Becton Dickinson (NYSE:BDX) Alaris system infusion pumps due to multiple system errors, software errors, and use-related errors.

All lots of five different models of the Alaris system were included in the recall that Becton Dickinson initiated on Feb. 4. In total, the company recalled 774,000 devices in the U.S. According to a news release, there have been 55 reported injuries and one death due to the issues. These were the affected models:

    • BD Alaris System PC Unit Model 8000, software versions 9.5 and prior.
    • BD Alaris System PC Unit Model 8015, software versions 9.33 and prior, and software version 12.1.0.
    • BD Alaris Pump Module Model 8100, software versions 9.33 and prior, and software version 12.1.0.
    • Alaris Syringe Module Model 8110, software versions 9.33 and prior, and software version 12.1.0.
    • Alaris PCA Module Model 8120, software versions 9.33 and prior, and software version 12.1.0.

Affected Alaris PC units with the software version 9.33 and older were distributed between July 2004 and Oct. 31, 2019, while the affected PC units with the software version 12.1.0 were distributed between Dec. 18, 2019, and Jan. 23, 2020, according to an FDA release.

The modules with the software version 9.33 and older have experienced software/system errors, delay options programming, low battery alarm failures, “keep vein open” (KVO) and “end of infusion” alarm priority issues and user-related errors with custom concentration programming.

Modules with software version 12.1.0 were reported to experience low battery alarm failures, KVO and “end of infusion” alarm priority issues, custom concentration programming user errors and the KVO rate was reportedly unavailable when using delay options programming.

The errors could lead to a delay in infusion, the interruption of infusion, slower-than-expected delivery of medication and faster-than-expected delivery of medication. BD/CareFusion 303 intend to contact all affected customers to begin the scheduling process for the necessary software update when the software is made available. Without the update, affected devices may remain vulnerable to the risk of the system and software errors.

BD’s Alaris system is an infusion pump and vital signs monitoring system designed to deliver fluids, medications, blood and blood products in controlled amounts.

In case you missed it

RSS From Medical Design & Outsourcing

  • How to choose the right printing technology for UDI codes
    UDI labeling can identify medical devices through their distribution and use. The deadline for labeling Class 1 and unclassified devices is coming up. Tim Kearns, Videojet Technologies Whether you are expanding the production of medical devices already subject to Unique Device Identification (UDI) requirements or finishing your plan to meet the FDA’s UDI requirements for… […]
  • 3 medtech execs make EY entrepreneur finalist list
    A trio of Minnesota medtech business leaders has landed on the finalist list for EY Entrepreneur of the Year 2021 Heartland. Executives from AbiliTech Medical, Minnesota Rubber & Plastics and TSI rank among the 36 finalists from Iowa, Kansas, Minnesota, Missouri, Nebraska, North Dakota and South Dakota. The finalists were selected by a panel of… […]
  • U.S. Supreme Court kicks Arthrex case back to patent board
    The U.S. Supreme Court ruled today that Patent Trial and Appeal Board judges are unconstitutionally appointed, but that greater supervision by the PTAB director would solve the problem. The opinion in the case followed a 2019 appeals court ruling in the closely watched patent spat between Arthrex and Smith+Nephew (NYSE:SNN). In the original lawsuit, Smith+Nephew and ArthroCare (which Smith+Nephew acquired… […]
  • Contract manufacturers fuel medtech expansion in Costa Rica
    Medical device manufacturing is flourishing in the Central American country, spurred by a host of incentives. This year is seeing a wave of expansions by medtech contract manufacturers in Costa Rica. Medtech OEMs have made the Central American company a manufacturing hub since the 1990s. Major companies operating there include Abbott, Bayer, Boston Scientific, Cardinal… […]
  • Purdue researchers develop biosensor for use during surgery
    Surgeons may soon be able to identify critical regions in tissues and organs during surgery using a biosensor recently developed at Purdue University. The biosensor can be printed in 3D using an automated printing system and allows for simultaneous recording and imaging of tissues and organs during surgery, according to its creator, Chi Hwan Lee.… […]
  • Amcor adds heat seal coating for medtech packaging
    Amcor has introduced a new heat seal coating for medical-grade DuPont Tyvek and paper packaging applications. The Buffalo Grove, Ill.-based company designed this next-generation coating technology to deliver enhanced performance features for healthcare applications. Amcor will produce the new coating, ACT2100, in multiple locations worldwide to offer customers the flexibility to receive supply from the… […]
  • Latest iCad 3D mammography AI gains CE mark
    iCad (NSDQ:ICAD) today announced that the third version of its ProFound AI for digital breast tomosynthesis (DBT) has won CE mark approval. Compared with previous software versions, the latest generation of ProFound AI offers up to a 10% improvement in specificity performance while maintaining a high sensitivity level and approximately 40% faster processing on the… […]
  • Device could reduce chemotherapy-induced pain
    Researchers in Singapore have partnered with Paxman Coolers (U.K.) to develop a device to prevent or reduce numbness and pain caused by chemotherapy. Chemotherapy-induced peripheral neuropathy (CIPN) is a severe side-effect of chemotherapy drugs called taxanes, which are used to treat common cancers such as breast, lung, ovarian and stomach cancer. CIPN affects about 1.4… […]
  • What medtech’s top executives learned from their dads
    For better or worse, parents including dads play a major role in who we become. With Father’s Day approaching in the U.S., Medical Design & Outsourcing and MassDevice reached out to some of medtech’s top executives to ask what they learned from their dads. Here’s what they said: “My father built a business in the… […]
  • FDA issues docs on medtech remanufacturing, servicing
    The FDA has issued two documents to help distinguish between remanufacturing and servicing of medical devices. One is a draft guidance written to clarify the activities that likely constitute the remanufacturing of a device. The other is a discussion paper on cybersecurity and medtech servicing. The guidance also describes the FDA’s current position on remanufacturing,… […]
  • HelixBind wins $3M grant for sepsis test
    HelixBind announced today it has landed a $3 million federal grant to help develop a test to diagnose bloodstream infections associated with sepsis. The FDA granted Breakthrough Device Designation to the RaPID/BSI test and platform in 2020. Boxborough, Mass.-based HelixBind’s RaPID platform can provide definitive identification and characterization of infections directly from a blood draw… […]